Baseline data for patients randomized to L-DNR vs idarubicin
| . | L-DNR . | Idarubicin . | P* . |
|---|---|---|---|
| n | 257 | 264 | |
| Age, y, median (Q1-Q3) | 9.8 (2.4-14.5) | 8.3 (2.2-14.1) | .28 |
| Leukocytes, ×103/µL, median (range) | 15 050 (4785-61 700) | 16 300 (4550-56 350) | .88 |
| Gender | .66 | ||
| Male | 135 (52) | 133 (50) | |
| Female | 122 (48) | 131 (50) | |
| CNS involvement, n/total n (%) | 22/252 (9) | 39/259 (15) | .03† |
| Extramedullary organ involvement | 67 (26) | 56 (21) | .19 |
| Cytogenetic data available, n/total n (%) | 239/257 (93) | 247/264 (94) | |
| Cytogenetic data | .11 | ||
| t(8;21) | 29 (12) | 29 (12) | |
| t(15;17) | 24 (10) | 14 (6) | |
| inv(16) | 24 (10) | 20 (8) | |
| Normal | 41 (17) | 63 (26) | |
| Other | 121 (51) | 121 (49) | |
| Risk groups | .68 | ||
| SR | 94 (37) | 92 (35) | |
| HR | 163 (63) | 172 (65) |
| . | L-DNR . | Idarubicin . | P* . |
|---|---|---|---|
| n | 257 | 264 | |
| Age, y, median (Q1-Q3) | 9.8 (2.4-14.5) | 8.3 (2.2-14.1) | .28 |
| Leukocytes, ×103/µL, median (range) | 15 050 (4785-61 700) | 16 300 (4550-56 350) | .88 |
| Gender | .66 | ||
| Male | 135 (52) | 133 (50) | |
| Female | 122 (48) | 131 (50) | |
| CNS involvement, n/total n (%) | 22/252 (9) | 39/259 (15) | .03† |
| Extramedullary organ involvement | 67 (26) | 56 (21) | .19 |
| Cytogenetic data available, n/total n (%) | 239/257 (93) | 247/264 (94) | |
| Cytogenetic data | .11 | ||
| t(8;21) | 29 (12) | 29 (12) | |
| t(15;17) | 24 (10) | 14 (6) | |
| inv(16) | 24 (10) | 20 (8) | |
| Normal | 41 (17) | 63 (26) | |
| Other | 121 (51) | 121 (49) | |
| Risk groups | .68 | ||
| SR | 94 (37) | 92 (35) | |
| HR | 163 (63) | 172 (65) |